South Korean vaccine developer SK bioscience’s shares were up 4.6% at 84,500 won, after it announced its decision to make an equity investment of around $85 million in US biotech Novavax. 9 August 2023
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
Swiss ophthalmology specialist Oculis Holding today released positive top-line results from its Phase III OPTIMIZE trial with OCS-01 eye drops. 8 August 2023
Nektar Therapeutics’ shares closed up a massive 82.6% at $0.98 yesterday, after it revealed announced that efficacy data previously generated by former partner Eli Lilly for Rezpeg (rezpegaldesleukin) that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly. 8 August 2023
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Germany’s BioNTech, which shot into the limelight with the development of the first and most successful COVID-19 vaccine, Comirnaty, partnered with Pfizer), today reported financial results for the three months ended June 30, 2023. 7 August 2023
Shares of UK-based biotech Roquefort Therapeutics were up 9.3% at 8.88 pence by early afternoon, as it announced the successful development of new siRNA sequences and new patent filing for its family of novel anti-cancer siRNA therapeutics. 7 August 2023
Sino-American biotech specializing in liver disease and cancer Terns Pharmaceuticals has announced that Senthil Sundaram has resigned from his position as Terns’ chief executive for health reasons previously disclosed in January 2022. 5 August 2023
Australian regenerative medicine company Mesoblast saw its shares plunge almost 57% to A$0.47 after it revealed a second setback in the development of it remestemcel-L. 4 August 2023
Privately-held UK biotech Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, USA. 4 August 2023
Agios Pharmaceuticals has signed exclusive worldwide license agreement with fellow USA-based Alnylam Pharmaceuticals to acquire the rights to develop and commercialize Alnylam’s novel pre-clinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera (PV). 4 August 2023
US autoimmune drug developer Kyverna Therapeutics today announced the close of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. 3 August 2023
Shares of UK clinical stage drug development company Evgen Pharma (AIM: EVG) were down more than 8% at 2.94 pence mid-morning, after it revealed that JuvLife Ltd, a division of Juvenescence, has terminated the patent and know-how license agreement for Evgen's Sulforadex sulforaphane stabilization technology. 2 August 2023
Age-related and autoimmune disease specialist MyMD Pharmaceuticals has announced positive Phase II data for its oral TNF-α inhibitor, MYMD-1. 1 August 2023
Traders looked unfavorably on Apellis Pharmaceuticals stock on Monday, after the company's report into the safety of its newly-approved Syfovre (pegcetacoplan) detailed a small number of retinal vasculitis cases. 1 August 2023
The US Food and Drug Administration has dealt a blow to the market value of New Jersey, USA-based oncology company Citius Pharmaceuticals. 31 July 2023
Shares in US genetic medicines company Homology Medicines leapt more than 35% to $1.34 last Friday, after it revealed it has completed a review of its business, and the board of directors has approved a plan to evaluate strategic alternatives to maximize shareholder value. 31 July 2023
Shares of Ionis Pharmaceuticals closed up 3.3% at $39.79 on Friday, after the US RNA-targeted drug developer revealed it has expanded its existing collaboration with AstraZeneca to include exclusive rights for the UK pharma major to commercialize eplontersen in Latin America 31 July 2023
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024